[go: up one dir, main page]

WO2003039435A3 - Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections - Google Patents

Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections Download PDF

Info

Publication number
WO2003039435A3
WO2003039435A3 PCT/BR2002/000157 BR0200157W WO03039435A3 WO 2003039435 A3 WO2003039435 A3 WO 2003039435A3 BR 0200157 W BR0200157 W BR 0200157W WO 03039435 A3 WO03039435 A3 WO 03039435A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
enteral
amphothericine
paraenteral
amphotercin
Prior art date
Application number
PCT/BR2002/000157
Other languages
French (fr)
Other versions
WO2003039435A2 (en
Inventor
Jose Maciel Rodrigues Junior
Gisele Santos Goncalves
Original Assignee
Univ Minas Gerais
Cristalia Produtos Quimicos E
Jose Maciel Rodrigues Junior
Gisele Santos Goncalves
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais, Cristalia Produtos Quimicos E, Jose Maciel Rodrigues Junior, Gisele Santos Goncalves filed Critical Univ Minas Gerais
Priority to AU2002347229A priority Critical patent/AU2002347229A1/en
Publication of WO2003039435A2 publication Critical patent/WO2003039435A2/en
Publication of WO2003039435A3 publication Critical patent/WO2003039435A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention has as its objective the process of obtaining of compositions containing amphotericin B in its superaggregate from capable of treating infections caused by fungi, parasites and other agents susceptible to this antibiotic. The invention covers the stable formulation of amphotericin B in its superaggregate form in presence of sodium deoxycholate, freeze-dried (lyophilized) and sterile, uniting the requirements for an injectable formulation for use enteral, parenteral or topical, with reduced toxicity in comparison to the conventional forms that transmit amphotericin B.
PCT/BR2002/000157 2001-11-05 2002-11-05 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections WO2003039435A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002347229A AU2002347229A1 (en) 2001-11-05 2002-11-05 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0105500-3 2001-11-05
BR0105500-3A BR0105500A (en) 2001-11-05 2001-11-05 Process for obtaining colloidal dispersions of amphotericin b; amphotericin b based compositions for enteral, parenteral and topical use; use of these compositions in the treatment of systemic mycoses and parasitic infections

Publications (2)

Publication Number Publication Date
WO2003039435A2 WO2003039435A2 (en) 2003-05-15
WO2003039435A3 true WO2003039435A3 (en) 2004-03-18

Family

ID=3948117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2002/000157 WO2003039435A2 (en) 2001-11-05 2002-11-05 Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections

Country Status (3)

Country Link
AU (1) AU2002347229A1 (en)
BR (1) BR0105500A (en)
WO (1) WO2003039435A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
CN110343650B (en) * 2019-05-28 2020-12-29 浙江工业大学 A recombinant Streptomyces tuberculosis producing amphotericin B and its application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591A (en) * 1983-05-26 1991-10-22 The Liposome Company, Inc. Drug preparations of reduced toxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591A (en) * 1983-05-26 1991-10-22 The Liposome Company, Inc. Drug preparations of reduced toxicity
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GABORIAU F. ET AL.: "Physico-chemical properties of the heat-induced 'superaggregates' of amphotericin B", BIOPHYSICAL CHEMISTRY, vol. 66, 1997, pages 1 - 12 *
JASEK W., AUSTRIA CODEX FACHINFORMATION 2002/2003, ISBN: 6-85200-150-1, article "Amphotericin B 'BMS' 50 mg-Trockensubstandz zur lokalen und systemische Anwendung", pages: 286 - 288 *
PETIT C. ET AL.: "In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating", J. ANTI CHEMO., vol. 42, pages 779 - 785 *

Also Published As

Publication number Publication date
AU2002347229A1 (en) 2003-05-19
WO2003039435A2 (en) 2003-05-15
BR0105500A (en) 2004-06-22

Similar Documents

Publication Publication Date Title
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
ZA200701629B (en) Gyrase inhibitors and uses thereof
EP4537828A3 (en) Phospholipid compounds and uses thereof
EA200501936A1 (en) PYRIDO [2,1-A] DERIVATIVES OF ISOHINOLINE AS DPP-IV INHIBITORS
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
MXPA03007777A (en) Amphotericin b aqueous composition.
WO2006081289A3 (en) Antibacterial agents
WO2006120563A3 (en) Antibacterial agents
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2006058648A3 (en) Biaryloxymethylarene carboxylic acids
WO2006107945A3 (en) Use of rip in treating staphylococcus aureus infections
WO2011019839A3 (en) Glycopeptide and lipoglycopeptide antibiotics with improved solubility
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
WO2003039435A3 (en) Process of obtaining colloidal dispersions of amphotercin b; compounds based on amphothericine b for enteral, paraenteral and topical use; use of these compounds in the treatment of systemic mycoses and parasitic infections
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
WO2005081821A3 (en) Polymorphic forms of 6-11 bicyclic ketolide derivatives
WO2006054182A3 (en) Phosphoindoles as hiv inhibitors
WO2004034961A3 (en) Antimicrobial agents and uses thereof
WO2022063869A3 (en) Compounds for the treatment of viral infections
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
WO2005070922A3 (en) Bis-indole pyrroles useful as antimicrobials agents
WO2007047881A3 (en) Method for treating neuropathic pain
DE60214889D1 (en) Sucroseoctasulphat silber saltz
WO2021258048A3 (en) Reagents, pharmaceutical formulations, and methods for treating and preventing viral infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP